BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27473816)

  • 1. Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy.
    Sapir E; Tao Y; Feng F; Samuels S; El Naqa I; Murdoch-Kinch CA; Feng M; Schipper M; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):354-361. PubMed ID: 27473816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.
    Vainshtein JM; Moon DH; Feng FY; Chepeha DB; Eisbruch A; Stenmark MH
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):925-33. PubMed ID: 25832685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.
    Lin A; Kim HM; Terrell JE; Dawson LA; Ship JA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):61-70. PubMed ID: 12909216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.
    Hunter KU; Schipper M; Feng FY; Lyden T; Haxer M; Murdoch-Kinch CA; Cornwall B; Lee CS; Chepeha DB; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):935-40. PubMed ID: 23040224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study.
    Vainshtein JM; Griffith KA; Feng FY; Vineberg KA; Chepeha DB; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):973-980. PubMed ID: 24803039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
    Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
    Hawkins PG; Lee JY; Mao Y; Li P; Green M; Worden FP; Swiecicki PL; Mierzwa ML; Spector ME; Schipper MJ; Eisbruch A
    Radiother Oncol; 2018 Jan; 126(1):68-74. PubMed ID: 28823405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.
    Eisbruch A; Kim HM; Terrell JE; Marsh LH; Dawson LA; Ship JA
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):695-704. PubMed ID: 11395238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study].
    Klausner G; Troussier I; Kreps S; Fabiano E; Laccourreye O; Giraud P
    Cancer Radiother; 2021 Dec; 25(8):771-778. PubMed ID: 34175226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gustatory disturbances occur in patients with head and neck cancer who undergo radiotherapy not directed to the oral cavity.
    Barbosa da Silva JL; Doty RL; Miyazaki JVMK; Borges R; Pinna FR; Voegels RL; Fornazieri MA
    Oral Oncol; 2019 Aug; 95():115-119. PubMed ID: 31345378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART).
    Ringash J; Fisher R; Peters L; Trotti A; O'Sullivan B; Corry J; Kenny L; Nuyts S; Wratten C; Rischin D
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):678-686. PubMed ID: 27209505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: Results of a prospective study.
    Tribius S; Raguse M; Voigt C; Münscher A; Gröbe A; Petersen C; Krüll A; Bergelt C; Singer S
    Strahlenther Onkol; 2015 Jun; 191(6):501-10. PubMed ID: 25747264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric and Clinical Outcomes With Intensity Modulated Radiation Therapy After Chemotherapy for Patients With Early-Stage Diffuse Large B-cell Lymphoma of Waldeyer Ring.
    Xu YG; Qi SN; Wang SL; Liu YP; Wang WH; Jin J; Song YW; Ren H; Fang H; He XH; Dong M; Chen B; Lu NN; Li N; Tang Y; Tang Y; Dai JR; Li YX
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):379-386. PubMed ID: 27478171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.